Amplia Therapeutics Ltd. ( (AU:ATX) ) just unveiled an update.
Amplia Therapeutics announced a positive outcome from its Type D meeting with the FDA regarding its planned clinical trial in the US for narmafotinib, a FAK inhibitor, in combination with FOLFIRINOX for advanced pancreatic cancer. The FDA’s approval of the proposed changes to the trial protocol allows Amplia to proceed with final planning stages, potentially positioning narmafotinib as a preferred drug in combination therapies for pancreatic cancer, enhancing its market position and offering promising prospects for stakeholders.
More about Amplia Therapeutics Ltd.
Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in the development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company focuses on fibrotic cancers such as pancreatic and ovarian cancer, and FAK’s role in chronic diseases like idiopathic pulmonary fibrosis (IPF).
YTD Price Performance: 82.93%
Average Trading Volume: 26,889
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $18.78M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.